Fatima Karzai

2.8k total citations
105 papers, 1.3k citations indexed

About

Fatima Karzai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Fatima Karzai has authored 105 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pulmonary and Respiratory Medicine, 60 papers in Oncology and 23 papers in Immunology. Recurrent topics in Fatima Karzai's work include Prostate Cancer Treatment and Research (68 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Immunotherapy and Immune Responses (22 papers). Fatima Karzai is often cited by papers focused on Prostate Cancer Treatment and Research (68 papers), Cancer Immunotherapy and Biomarkers (37 papers) and Immunotherapy and Immune Responses (22 papers). Fatima Karzai collaborates with scholars based in United States, Italy and New Zealand. Fatima Karzai's co-authors include James L. Gulley, Ravi A. Madan, William L. Dahut, Marijo Bilušić, Jeffrey Schlom, Renee N. Donahue, Jennifer L. Marté, Julius Strauss, Lisa M. Cordes and Margaret E. Gatti‐Mays and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Fatima Karzai

97 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fatima Karzai United States 18 648 420 370 362 240 105 1.3k
Chiara Corti Italy 25 1.3k 2.0× 442 1.1× 284 0.8× 466 1.3× 334 1.4× 70 1.9k
Stefan Kasper Germany 24 885 1.4× 397 0.9× 448 1.2× 636 1.8× 190 0.8× 122 2.0k
Andrea Forschner Germany 24 1.2k 1.9× 221 0.5× 392 1.1× 616 1.7× 182 0.8× 107 1.7k
Robin Cornelissen Netherlands 25 938 1.4× 1.3k 3.2× 293 0.8× 218 0.6× 176 0.7× 98 1.9k
Guillermo Villacampa Spain 14 587 0.9× 327 0.8× 115 0.3× 226 0.6× 264 1.1× 90 1.1k
G. Daniel Grass United States 19 493 0.8× 348 0.8× 282 0.8× 611 1.7× 241 1.0× 78 1.5k
Geoffrey Kim United States 18 621 1.0× 354 0.8× 156 0.4× 205 0.6× 142 0.6× 29 1.0k
J. Thaddeus Beck United States 19 1.4k 2.1× 740 1.8× 123 0.3× 551 1.5× 619 2.6× 74 2.1k
Benjamin L. Maughan United States 22 915 1.4× 1.4k 3.4× 192 0.5× 541 1.5× 707 2.9× 167 2.1k
Julia Wilkerson United States 20 608 0.9× 713 1.7× 99 0.3× 501 1.4× 284 1.2× 44 1.8k

Countries citing papers authored by Fatima Karzai

Since Specialization
Citations

This map shows the geographic impact of Fatima Karzai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatima Karzai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatima Karzai more than expected).

Fields of papers citing papers by Fatima Karzai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatima Karzai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatima Karzai. The network helps show where Fatima Karzai may publish in the future.

Co-authorship network of co-authors of Fatima Karzai

This figure shows the co-authorship network connecting the top 25 collaborators of Fatima Karzai. A scholar is included among the top collaborators of Fatima Karzai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatima Karzai. Fatima Karzai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bracken‐Clarke, Dara, Danielle M. Pastor, Jennifer L. Marté, et al.. (2026). The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer. The Oncologist. 31(3).
2.
Iannantuono, Giovanni Maria, Charalampos S. Floudas, Marco Filetti, et al.. (2025). Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023). European Journal of Cancer. 225. 115589–115589.
3.
Iannantuono, Giovanni Maria, Dara Bracken‐Clarke, Fatima Karzai, et al.. (2024). Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. The Oncologist. 29(5). 407–414. 23 indexed citations
4.
Karzai, Fatima, et al.. (2024). Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. JNCI Journal of the National Cancer Institute. 116(7). 1063–1071. 5 indexed citations
5.
6.
Wang, Hao, Dalang Fang, Jinxin Zhu, et al.. (2024). Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer. Translational Andrology and Urology. 13(9). 2092–2109. 2 indexed citations
7.
Cordes, Lisa M., Fatima Karzai, William D. Figg, & Ravi A. Madan. (2023). Relugolix in Clinical Practice: The Best Route for All?. The Oncologist. 28(8). 647–650. 6 indexed citations
8.
Iannantuono, Giovanni Maria, Charalampos S. Floudas, Hyoyoung Choo‐Wosoba, et al.. (2023). Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treatment Reviews. 120. 102623–102623. 15 indexed citations
9.
Atiq, Mohammad, et al.. (2023). Emerging treatment options for prostate cancer. Expert Review of Anticancer Therapy. 23(6). 625–631. 8 indexed citations
10.
Gatti‐Mays, Margaret E., Nicholas Tschernia, Julius Strauss, et al.. (2023). A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. The Oncologist. 28(4). 364–e217. 9 indexed citations
11.
Madan, Ravi A., Fatima Karzai, David James VanderWeele, Heather H. Cheng, & Johann S. de Bono. (2023). Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. Journal of Clinical Oncology. 41(36). 5501–5504. 5 indexed citations
12.
Bilušić, Marijo, Renee N. Donahue, Susan Wróblewski, et al.. (2022). A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases. 25(4). 735–740. 17 indexed citations
13.
Bilušić, Marijo, Sheri McMahon, Ravi A. Madan, et al.. (2021). Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer. 9(3). e002374–e002374. 43 indexed citations
14.
Strauss, Julius, Margaret E. Gatti‐Mays, Byoung Chul Cho, et al.. (2021). 957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Annals of Oncology. 32. S829–S829. 5 indexed citations
15.
Madan, Ravi A., Susan F. Slovin, Lauren C. Harshman, et al.. (2020). 681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc). Annals of Oncology. 31. S542–S542. 1 indexed citations
16.
Madan, Ravi A., Keith T. Schmidt, Fatima Karzai, et al.. (2020). Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer. 18(4). 258–267.e1. 14 indexed citations
17.
Trostel, Shana Y., Olga Voznesensky, Rachel Schaefer, et al.. (2019). Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precision Oncology. 3(3). 1–13. 49 indexed citations
18.
Beshiri, Michael L., Caitlin M. Tice, Crystal Tran, et al.. (2018). A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research. 24(17). 4332–4345. 145 indexed citations
19.
Miyahira, Andrea K., Robert B. Den, Maria I. Carlo, et al.. (2018). Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting. The Prostate. 79(3). 244–258. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiara Corti Breakdown of academic impact, for papers by Stefan Kasper Breakdown of academic impact, for papers by Andrea Forschner Breakdown of academic impact, for papers by Robin Cornelissen Breakdown of academic impact, for papers by Guillermo Villacampa Breakdown of academic impact, for papers by G. Daniel Grass Breakdown of academic impact, for papers by Geoffrey Kim Breakdown of academic impact, for papers by J. Thaddeus Beck Breakdown of academic impact, for papers by Benjamin L. Maughan Breakdown of academic impact, for papers by Julia Wilkerson
Rankless by CCL
2026